Core Outcome Set for GROwth restriction: deVeloping Endpoints (COSGROVE)

Healy, Patricia; Gordijn, Sanne; Ganzevoort, Wessel; Beune, Irene; Baschat, Ahmet; Khalil, Asma; Kenny, Louise; Bloomfield, Frank; Daly, Mandy; Papageorghiou, Aris; Devane, Declan

Core Outcome Set for GROwth restriction: deVeloping Endpoints (COSGROVE)

cb

Files

s13063-018-2819-9.pdf(571.12 KB)

Published version

Date

2018-08-22

Authors

Healy, Patricia

Gordijn, Sanne

Ganzevoort, Wessel

Beune, Irene

Baschat, Ahmet

Khalil, Asma

Kenny, Louise

Bloomfield, Frank

Daly, Mandy

Papageorghiou, Aris

Show 1 more

Publisher

BioMed Central

Published Version

10.1186/s13063-018-2819-9

Abstract

Foetal growth restriction (FGR) refers to a foetus that does not reach its genetically predetermined growth potential. It is well recognised that growth-restricted foetuses are at increased risk of stillbirth, foetal compromise, early neonatal death and neonatal morbidity. Later in life, they are prone to health problems, including increased risk of cardiovascular diseases and neurodevelopmental disorders. Interventions for preventing and treating FGR have been studied in many trials, but evidence is often difficult to synthesise and compare because of differences in the selection and definition of outcomes. To enable future trials to measure similar, meaningful outcomes, we are developing two core outcome sets (COS) – one for prevention and the other for treatment of FGR.

Keywords

Core outcome sets , Delphi , Methodology , Foetal growth restriction , Pregnancy

Citation

Healy, P., Gordijn, S., Ganzevoort, W., Beune, I., Baschat, A., Khalil, A., Kenny, L., Bloomfield, F., Daly, M., Papageorghiou, A. and Devane, D., 2018. Core Outcome Set for GROwth restriction: deVeloping Endpoints (COSGROVE). Trials, 19(1), (451). DOI: 10.1186/s13063-018-2819-9